For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Norverapamil is a calcium channel blocker, it is the main active metabolite of verapamil.<br>In vitro: Norverapamil is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil.[1] Norverapamil (NOR) is the major metabolite and shows approximately 20% of the efficacy of VER with regard to the vasodilation effect, but shows no antiarrhythmic activity. [2] Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic. [3]</p>
Catalog Number | I004551 |
CAS Number | 67812-42-4 |
Synonyms | D 591 |
Molecular Formula | C26H36N2O4 • HCl |
Purity | ≥95% |
Target | Neuronal Signaling |
Solubility | DMSO ≥ 31 mg/mL |
Storage | -20°C |
InChIKey | OEAFTRIDBHSJDC-UHFFFAOYSA-N |
Reference | <p style=/line-height:25px/> <br>[2]. Singhal P et al. Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. J Chromatogr Sci. 2012 Oct;50(9):839-48. <br>[3]. Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302. </p> |